# Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

> **NCT00005991** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 76 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** pegylated liposomal doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00005991
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-08-25
- **Primary completion:** 2003-02-14
- **Final completion:** 2003-02-14
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2018-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005991, "Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00005991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*